Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin CH0012032048
Ticker ROG.VX
Company ROCHE
Currency CHF
Price
Aware Investor Index (AII) 167.5811
Recommendation STRONG BUY
P/E 8.80
ROE 31.75 %
Capitalization 83,692,492,548 $
Dividend Yield 8.81 %
P/S 1.52
AII Position 27
P/E Position 40
ROE Position 90
Capitalization Position 112
Dividend Yield Position 23
Sales 53,299,000,000 CHF
10-Year Average Earnings 9,210,600,000 CHF
Shares Outstanding 860,000,000
Equity 29,007,000,000 CHF
Dividend per Share 8.3 CHF
Industry Pharmaceutical
Country Switzerland
ROCHE Investor Relations Web Site http://www.roche.com/investors.htm







Sales:

YEAR MONTH AMOUNT
2017 12 53,299,000,000.00 CHF
2016 12 50,576,000,000.00 CHF
2015 12 48,145,000,000.00 CHF
2014 12 47,462,000,000.00 CHF
2013 12 46,780,000,000.00 CHF

Earnings:

YEAR MONTH AMOUNT
2017 12 8,825,000,000.00 CHF
2016 12 9,733,000,000.00 CHF
2015 12 8,863,000,000.00 CHF
2014 12 9,332,000,000.00 CHF
2013 12 11,164,000,000.00 CHF
2012 12 9,427,000,000.00 CHF
2011 12 9,343,000,000.00 CHF
2010 12 8,666,000,000.00 CHF
2009 12 7,784,000,000.00 CHF
2008 12 8,969,000,000.00 CHF

Equity:

YEAR MONTH AMOUNT
2017 12 29,007,000,000.00 CHF
2016 12 26,402,000,000.00 CHF
2015 12 23,300,000,000.00 CHF
2014 12 21,558,000,000.00 CHF
2013 12 21,241,000,000.00 CHF
2012 12 16,728,000,000.00 CHF
2011 12 14,482,000,000.00 CHF

Shares Outstanding:

YEAR MONTH AMOUNT
2017 12 860,000,000
2016 12 860,000,000
2015 12 862,000,000
2014 12 863,000,000
2013 12 863,000,000
2012 12 848,000,000
2011 12 849,000,000

 












Bloomberg News for ROCHE:



Google News for ROCHE:

Wall Street Journal - 28 Apr 2019
Cancer-Drug Giant Roche Loses Edge as Rivals Grow
Roche's cancer franchise generated double the sales of its nearest competitor in 2018 but is expected to shrink over the next few years.
industryreports24.com - 30 Apr 2019
Orphan Drugs Market with top key players like Bristol-Myers Squibb ...
Orphan Drugs Market with top key players like Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd., Pfizer, Inc., ...
Bloomberg - 30 Jan 2019
Biogen Slips as Roche Spikes Alzheimer's Trials on Weak Data
Shares of Biogen Inc. came under pressure in trading before the U.S. market opened Wednesday after peer Roche Holding AG halted a pair of ...
WallStreet.org - 17 Apr 2019
Roche Lifts Full Year Outlook, Sees Higher Dividend Following ...
Swiss drugmaker Roche (ROG.VX) said early Wednesday that it started the year with “strong” sales growth in the first quarter, driven by newly ...
Seeking Alpha - 5 Feb 2019
Selling Roche: Sector And Company-Specific Reasons
I took (modest) profits in Roche ADRs very recently, for industry-related and company-specific reasons. I suspect that many Big Pharma-Biotech ...
Seeking Alpha - 17 Apr 2019
Roche Holding AG 2019 Q1 - Results - Earnings Call Slides
Roche Holding AG 2019 Q1 - Results - Earnings Call Slides ... The following slide deck was published by Roche Holding AG in conjunction ...
Seeking Alpha - 17 Apr 2019
Roche Holding AG (RHHBY) CEO Severin Schwan on Q1 2019 ...
Roche Holding AG (OTCQX:RHHBY) Q1 2019 Results Earnings Conference Call April 17, 2019 8:00 AM ET. Company Participants. Severin ...
Forbes - 13 Mar 2019
How Much Can Roche's Share Price Grow If Ocrevus Doubles Its ...
Roche Holding's (NASDAQ:RHHBY) Ocrevus has been on a stellar run with sales exceeding $2.4 billion in 2018, reflecting a growth of 2.8x ...
Yahoo Finance - 24 Apr 2019
The Zacks Analyst Blog Highlights: Roche, Danaher, BlackRock ...
For Immediate Release. Chicago, IL – April 24, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks ...
Bloomberg - 17 Apr 2019
Roche CEO Schwan Says New Medicines Driving 'Strong Growth'
Roche Holding AG Chief Executive Officer Severin Schwan talks about the company's financial results, outlook and strategy. Roche increased ...


Back